MedTrace Logo

Long-term Study to Evaluate and Clinical Outcomes in Patients With Favorable Intermediate Risk Localized Prostate Cancer

NCT03290508 · Status: TERMINATED · Type: OBSERVATIONAL · Enrollment: 524

Last updated 2022-06-23

No results posted yet for this study

Summary

This is a long-term prospective registry study to determine whether Prolaris testing in patients with favorable intermediate risk prostate cancer influences physician management decisions toward conservative treatment in patients with Prolaris low-risk scores without negatively impacting patient oncologic outcomes, thereby sparing low-risk patients from unnecessary treatments and associated side-effects.

Conditions

Interventions

DIAGNOSTIC_TEST

Prolaris Testing

Recently diagnosed treatment-naïve patients with early stage localized prostate cancer who undergo Prolaris testing

Sponsors & Collaborators

  • Myriad Genetic Laboratories, Inc.

    lead INDUSTRY

Eligibility

Min Age
65 Years
Sex
MALE
Healthy Volunteers
No

Timeline & Regulatory

Start
2017-09-14
Primary Completion
2022-01-14
Completion
2022-01-14

Countries

  • United States

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03290508 on ClinicalTrials.gov